Dr. Wang Yinxiang is currently Chairman and CEO of Jacobio.
Dr. Wang Yinxiang has more than 30 years of experience oncology research. He once led the research and marketing of icotinib hydrochloride (Conmana®, the first targeted anti-tumor drug in China). Before he established Jacobio, he served as President and CSO of Betta Pharmaceuticals (300558.SZ).
Dr. Wang Yinxiang earned his Ph.D. from the University of Arkansas for Medical Sciences, USA. After that, he was engaged in postdoctoral research in the Department of Molecular Biophysics and Biochemistry, Yale University. Now, he is the vice chairman of the Anti-tumor Drug Professional Committee of the Chinese Pharmaceutical Association, and vice chairman of the New Drug R&D Committee of the China Pharmaceutical Innovation and Research Development Association (PHIRDA).
Wang Xiaojie is currently the President of Administration of Jacobio and also serves as Executive Director of Board.
Fully committed to Jacobio’s strategy of targeting the global market, Wang Xiaojie is in charge of the operation and management of supporting departments of the company, including human resources, finance, legal affairs, government affairs and investor relations. She has more than 20 years of leadership experience in the pharmaceutical industry and previously served as Vice President at Betta Pharmaceuticals (300558.SZ).
Wang Xiaojie graduated from Dalian Polytechnic University with a bachelor’s degree and completed an executive MBA program at Peking University.
Hu Yunyan is currently Executive Vice President of Jacobio and also serves as Executive Director of Board.
Hu Yunyan is in charge of the company’s quality management system, responsible for quality and regulatory compliance work, and supervises regulatory compliance in laboratory, clinical, pharmacovigilance, and production.
She has more than 20 years of practical experience in the pharmaceutical industry. Before joining Jacobio, she worked at Betta Pharmaceuticals (300558.SZ) and led the chemistry, manufacturing, and controls (CMC) work for icotinib hydrochloride (Conmana®, the first targeted anti-tumor drug in China). Based on her outstanding contributions, she was granted the title of “Beijing Model Worker” in 2015.
Hu Yunyan earned a master’s degree in analytical chemistry from the Lanzhou Institute of Chemical Physics of the Chinese Academy of Sciences.
Ms. Tang Yanmin joined the Board of Directors on August 2018 and is currently a non-executive director.
Ms. Tang focuses on investments in the healthcare sector and is currently an investment partner at Qiming Venture Partners. Before joining Qiming Venture Partners, she spent 13 years (2002-2015) at Morningside Ventures, where she invested in and sat on the boards of over 20 early-stage biopharmaceutical companies. Most of those investments have successfully exited through IPOs or M&A transactions. Prior to joining Morningside ventures, Ms. Tang worked for GlaxoSmithKline.
Ms. Tang earned a bachelor’s degree from Shenyang Pharmaceutical University and completed an Executive MBA program and obtained a master’s degree from Cheung Kong Graduate School of Business.
Dr. Chen Te-li joined Jacobio’s Board of Directors in August 2020 and is currently a non-executive director.
Dr. Chen has more than 27 years of experience in the medical industry. In 2016 he founded and then served as the general manager of BioGend Therapeutics, which focuses on the research and development of pharmaceuticals and medical materials. Dr. Chen is also currently a professor at the Institute of Medical Sciences of National Defense Medical Center. Earlier, he worked as a physician at Taipei Veterans General Hospital and as an associate professor of internal medicine at National Yang-Ming University.
Dr. Chen obtained his doctoral degree from the Institute of Tropical Medicine of the National Yang-Ming University in Taiwan. Dr. Chen was certified as a physician by the Ministry of Health and Welfare in Taiwan in 1995.
Dr. Song is dedicated to the research of China’s pharmaceutical policies, especially pharmaceutical innovation policies. Dr. Song has served as a member of the council of the Chinese Pharmaceutical Association since November 2009 and a member of the Pharmaceuticals Management Expert Committee of the Association since July 2016. Dr. Song is currently the president of the China Pharmaceutical Innovation and Research Development Association.
Dr. Song obtained a bachelor’s degree in law from China University of Political Science and Law, a master’s degree in business administration from the China Europe International Business School and a doctoral degree in social and administrative pharmacy from China Pharmaceutical University.
Dr. Lu Bai joined Jacobio’s Board of Directors in March 22, 2023 and is currently an independent non-executive director.
Dr. Lu has long been committed to the research of neurotrophic factors and synaptic plasticity, as well as neurodegenerative and psychiatric diseases, and is an internationally renowned neurobiologist. In 2013, Dr. Lu became a professor and the Executive Vice Dean, in charge of Tsinghua Univ. Medical School. Starting from Jan. 2016, he became a professor of the newly established School of Pharmaceutical Sciences. Dr. Lu was recruited to the GlaxoSmithKline (GSK) R&D Center as the vice president in China in 2009. Earlier, he was the Chief of Neural Development and Plasticity Section, and the Associate Director of a trans-NIH translational research program (GCAP).
Dr. Lu obtained a doctoral degree from Cornell University in 1990 and then worked in postdoctoral research at Rockefeller University from 1990 to 1993.
Dr. Wu has extensive experience in financial management and accounting. Dr. Wu served as a lecturer from September 1994 to July 2001, an associate professor from July 2001 to December 2005 and a full professor since December 2005 at the Accounting Department of the International Business School of the University of International Business and Economics.
Dr. Wu earned a bachelor’s degree in mathematics from Nanjing Normal University in July 1989, a master’s degree in accounting from Nankai University in June 1994 and a doctoral degree in finance from the University of International Business and Economics in June 2008.